A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults
NCT07679282 is a phase 4 interventional trial sponsored by Sairam Parthasarathy. As of 21 Nov 2026, it is recruiting participants. It studies Atomoxetine-oxybutynin in Obstructive Sleep Apnea (OSA). The registry lists an enrollment of 2,400 participants at 4 sites in 1 country. The registry lists a start date of 4 Sept 2026 and a primary completion date of 1 Mar 2030.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07679282 |
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Sairam Parthasarathy |
| Enrollment | 2,400 |
| Registered sites | 4 |
| Countries | 1 |
| Conditions | Obstructive Sleep Apnea (OSA) |
| Drugs | Atomoxetine-oxybutynin |
| Start | 4 Sept 2026 |
| Primary completion | 1 Mar 2030 |
| Study completion | 1 May 2032 |
| Last update posted | 19 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Sairam Parthasarathy, MD
University of Arizona
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Banner University Medical Center Tucson
Tucson
Monisha Das Ireland, MDSaif Mashaqi, MDSairam Parthasarathy, MDRecruiting
- Stanford Medical Center
Redwood City
Clete Kushida, MD, PhDRecruiting
- University of Miami Miller School of Medicine
Miami
Alexandre Abreu, MDGirardin Jean-Louis, PhDNot, yet, recruiting
- University of Maryland Baltimore
Baltimore
Emerson Wickwire, PhDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07679282
Each answer restates registry values shown on this page.
What is NCT07679282?
NCT07679282 is a phase 4 interventional trial sponsored by Sairam Parthasarathy. It studies Atomoxetine-oxybutynin in Obstructive Sleep Apnea (OSA).
Is NCT07679282 recruiting?
As of 21 Nov 2026, it is recruiting participants. 3 of its 4 sites list their own status as recruiting.
Who leads NCT07679282?
The registry names Sairam Parthasarathy, MD (principal investigator, University of Arizona) as the overall official.
Where does NCT07679282 run?
The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07679282 study?
The registered drug and biological interventions are Atomoxetine-oxybutynin.
When is NCT07679282 expected to complete?
The registry lists a primary completion date of 1 Mar 2030 and a study completion date of 1 May 2032. The sponsor last updated the record on 19 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.